Story

Trulieve Stock Rallies on First Earnings Report Since Cannabis Rescheduling

ENTHMSVIIDZHZH-TWJAKOHI
Aug 7, 20262 min read
Trulieve Stock Rallies on First Earnings Report Since Cannabis Rescheduling
Text size
Background

Trulieve Cannabis Corp. (TRLV) shares rallied in pre-market trading after the company released its second-quarter 2026 financial results, the first full reporting period since the landmark federal rescheduling of medical cannabis. Investors are closely watching for details on how the significant regulatory shift is impacting the company's profitability and cash flow.

First Results Under New Rules

Shares of the multi-state operator gained 5.6% to reach $9.50 in pre-open trading, according to Investing.com. The move follows the release of Trulieve's earnings for the three months ending in June, a period that fully captures the impact of the U.S. government's decision in April 2026 to reclassify medical cannabis from Schedule I to Schedule III.

This reclassification is a transformative event for the industry, as it relieves state-legal medical operators from the punitive Internal Revenue Code Section 280E. That tax provision previously barred cannabis companies from deducting ordinary business expenses, severely impacting their bottom lines. The elimination of 280E is expected to significantly boost margins and free cash flow.

Analyst Expectations and Outlook

Heading into the report, Wall Street held a constructive view on Trulieve. According to the source, consensus estimates pointed to:

Sample IUX Markets – In-articleAd
  • Earnings of approximately 8 cents per share.
  • Revenue of around $272 million, a modest sequential decrease from Q1's $286.8 million and in line with management's prior guidance.

Analyst sentiment is uniformly bullish, with all seven analysts covering the stock holding Buy-equivalent ratings. The average 12-month price target stood near $18.71, more than double the stock's previous closing price. This positive outlook has been bolstered by growing institutional interest since the company's uplisting to the NYSE in June 2026.

Focus on Management Commentary

Investors are now awaiting a conference call scheduled for 8:30 AM Eastern Time, where CEO Kim Rivers and CFO Jan Reese will provide further details. Market participants will be listening for specific commentary on the tangible financial benefits of 280E relief, including margin expansion, cash flow generation, and the company's updated full-year outlook in the new regulatory landscape.

Read next

More on Stocks
Back to latest news

LATEST